LES LABORATOIRES SERVIER

Company Snapshot

Founded: 1954

Entity Type: Private

Headquarter: France

Key Geographics: North America, South America, Europe, Asia-Pacific, Middle East and Africa

Corporate Address: 50, rue Carnot 92284 Suresnes France Tel: +33-(0)1-55-72-60-00 Web: www.servier.com

Company Overview

Servier is an independent pharmaceutical company governed by a non-profit foundation, the Fondation Internationale de Recherche Servier (FIRS). The company’s focus areas are oncology, cardio metabolism & veinous diseases, neuroscience and immuno-inflammation. Servier invests over 20% of its revenue from brand-name drugs in R&D each year. It was the first company to deliver an IDH inhibitor drug. The company has 15 production sits and produces over 96% of the active ingredients used in its brand-name medicines in France. The company’s products are marketed in over 150 countries.

LES LABORATOIRES SERVIER In Reports

Global Pharmaceutical Drugs Industry: Competitive Landscape 2023

BCC Research Report: Dive into pharmaceutical drugs market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this report.

Nanotechnology in Cancer Treatment: Technologies and Global Markets

BCC Research Report: Dive into Nanotechnology in Cancer Treatments market report includes global revenue ($ Million) for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market

BCC Research Report: Dive into Chimeric Antigen Receptor (CAR) T-Cell Therapy Market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029.

View All Reports

LES LABORATOIRES SERVIER In News

Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology - insilico.com

insilico.com - Jan 04, 2026

Servier completes the acquisition of Day One Biopharmaceuticals - PR Newswire

PR Newswire - Apr 23, 2026

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio - Servier

Servier - Mar 06, 2026

Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily

Oncodaily - Mar 12, 2026

Read All News

Company's Business Segments

Cancer : It offers therapeutic products for hematologic cancers, brain tumors, and digestive cancers.
Cardiometabolism : It offers products for Cardiovascular, metabolic, and venous diseases (CMVD).
Neurology : It offers products for rare neurological diseases.

Applications/End User Industries

Healthcare
Pharmaceutical

Life Sciences

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment